CL2016003014A1 - Anticuerpos monoclonales contra el inhibidor de la vía del factor tisular (tfpi) (divisional sol. n°230-11). - Google Patents

Anticuerpos monoclonales contra el inhibidor de la vía del factor tisular (tfpi) (divisional sol. n°230-11).

Info

Publication number
CL2016003014A1
CL2016003014A1 CL2016003014A CL2016003014A CL2016003014A1 CL 2016003014 A1 CL2016003014 A1 CL 2016003014A1 CL 2016003014 A CL2016003014 A CL 2016003014A CL 2016003014 A CL2016003014 A CL 2016003014A CL 2016003014 A1 CL2016003014 A1 CL 2016003014A1
Authority
CL
Chile
Prior art keywords
tfpi
monoclonal antibodies
antibodies against
tissue factor
pathway inhibitor
Prior art date
Application number
CL2016003014A
Other languages
English (en)
Inventor
Zhuozhi Wang
Junliang Pan
Haiyan Jiang
John E Murphy
Bing Liu
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41664165&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016003014(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of CL2016003014A1 publication Critical patent/CL2016003014A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<p>COMPOSICIÓN QUE COMPRENDE ANTICUERPOS MONOCLONALES CONTRA EL INHIBIDOR DE LA VÍA DEL FACTOR TISULAR (TFPI); Y USO PARA TRATAR DEFICIENCIA DE COAGULACIÓN.</p>
CL2016003014A 2008-08-04 2016-11-24 Anticuerpos monoclonales contra el inhibidor de la vía del factor tisular (tfpi) (divisional sol. n°230-11). CL2016003014A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8598008P 2008-08-04 2008-08-04

Publications (1)

Publication Number Publication Date
CL2016003014A1 true CL2016003014A1 (es) 2017-06-30

Family

ID=41664165

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2011000230A CL2011000230A1 (es) 2008-08-04 2011-02-03 Anticuerpo monoclonal humano aislado que se une al inhibidor de la via del factor tisular (tfpi); composicion farmaceutica que lo comprende; uso para tratar deficiencias adquiridas o geneticas de la coagulacion, o para acortar el tiempo de sangrado.
CL2016003015A CL2016003015A1 (es) 2008-08-04 2016-11-24 Anticuerpos monoclonales contra el inhibidor de la vía del factor tisular (tfpi)(divisional de sol. n°230-11).
CL2016003014A CL2016003014A1 (es) 2008-08-04 2016-11-24 Anticuerpos monoclonales contra el inhibidor de la vía del factor tisular (tfpi) (divisional sol. n°230-11).

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CL2011000230A CL2011000230A1 (es) 2008-08-04 2011-02-03 Anticuerpo monoclonal humano aislado que se une al inhibidor de la via del factor tisular (tfpi); composicion farmaceutica que lo comprende; uso para tratar deficiencias adquiridas o geneticas de la coagulacion, o para acortar el tiempo de sangrado.
CL2016003015A CL2016003015A1 (es) 2008-08-04 2016-11-24 Anticuerpos monoclonales contra el inhibidor de la vía del factor tisular (tfpi)(divisional de sol. n°230-11).

Country Status (36)

Country Link
US (3) US20120269817A1 (es)
EP (1) EP2321356B1 (es)
JP (1) JP5801194B2 (es)
KR (5) KR101769725B1 (es)
CN (4) CN105944100B (es)
AU (3) AU2009279804C1 (es)
BR (2) BR122017025538A2 (es)
CA (4) CA2733075C (es)
CL (3) CL2011000230A1 (es)
CO (1) CO6351803A2 (es)
CR (1) CR20110066A (es)
CU (2) CU23880B1 (es)
CY (1) CY1120670T1 (es)
DK (1) DK2321356T3 (es)
DO (2) DOP2011000045A (es)
EC (1) ECSP11010810A (es)
ES (1) ES2677329T3 (es)
HR (1) HRP20181095T1 (es)
HU (1) HUE038648T2 (es)
IL (4) IL210987A (es)
LT (1) LT2321356T (es)
MX (1) MX2011001351A (es)
MY (1) MY161844A (es)
NZ (2) NZ714313A (es)
PE (2) PE20110771A1 (es)
PH (1) PH12017502286A1 (es)
PL (1) PL2321356T3 (es)
PT (1) PT2321356T (es)
SG (1) SG10201703066PA (es)
SI (1) SI2321356T1 (es)
SM (1) SMT201800355T1 (es)
SV (1) SV2011003828A (es)
TR (1) TR201807252T4 (es)
UA (2) UA112050C2 (es)
WO (1) WO2010017196A2 (es)
ZA (1) ZA201100888B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2379096B1 (en) 2008-12-19 2019-10-30 Baxalta GmbH Tfpi inhibitors and methods of use
WO2010072691A1 (en) * 2008-12-22 2010-07-01 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
SI3409289T1 (sl) * 2010-02-26 2020-12-31 Novo Nordisk A/S Stabilni sestavki, ki vsebujejo protitelo
AU2016269554B2 (en) * 2010-03-01 2018-12-20 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
PT2542257T (pt) * 2010-03-01 2017-10-09 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
AU2013202745B2 (en) * 2010-03-01 2017-01-05 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
ES2983470T3 (es) * 2010-03-19 2024-10-23 Takeda Pharmaceuticals Co Inhibidores del TFPI y métodos de uso
RU2012153786A (ru) * 2010-05-28 2014-07-10 Ново Нордиск А/С Стабильные многодозовые композиции, содержащие антитело и консервант
TW201212938A (en) 2010-06-30 2012-04-01 Novo Nordisk As Antibodies that are capable of specifically binding tissue factor pathway inhibitor
US9228022B2 (en) 2010-06-30 2016-01-05 Novo Nordisk A/S Antibodies that are capable of specifically binding tissue factor pathway inhibitor
ES2722824T3 (es) * 2011-04-01 2019-08-19 Bayer Healthcare Llc Anticuerpos monoclonales contra el inhibidor de la ruta del factor tisular (TFPI)
BR112014022435B1 (pt) 2012-03-21 2023-02-14 Takeda Pharmaceutical Company Limited Inibidores de tfpi e métodos de uso
WO2013148248A1 (en) * 2012-03-30 2013-10-03 Bayer Healthcare Llc Protease-regulated antibodies
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
CN113788897A (zh) 2013-03-15 2021-12-14 拜尔健康护理有限责任公司 改善药代动力学的具有跨pH范围差异结合的抗TFPI抗体变体
WO2015007880A1 (en) * 2013-07-19 2015-01-22 Novo Nordisk A/S Antibodies recognizing the n-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity
US11279771B2 (en) 2014-09-17 2022-03-22 Novo Nordisk A/S Antibodies capable of binding two epitopes on tissue factor pathway inhibitor (1-161)
MX388251B (es) * 2015-02-25 2025-03-19 Mogam Inst Biomedical Res Nuevo anticuerpo que se una a tfpi y composicion que comprende el mismo.
EP3337827B1 (en) 2015-08-19 2026-07-08 Pfizer Inc. Tissue factor pathway inhibitor antibodies and uses thereof
JP6419664B2 (ja) * 2015-08-26 2018-11-07 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
JP6559188B2 (ja) * 2017-07-06 2019-08-14 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
JP2018038398A (ja) * 2017-09-04 2018-03-15 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
JP2018108089A (ja) * 2018-02-19 2018-07-12 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
CN109053882B (zh) * 2018-08-28 2019-08-23 东莞市朋志生物科技有限公司 一种ns1蛋白的结合蛋白以及应用
EP3863664A1 (en) 2018-10-11 2021-08-18 Pfizer Inc. Dosage regimen for tfpi antagonists
JP6848016B2 (ja) * 2019-07-16 2021-03-24 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
CN112442127A (zh) * 2019-08-29 2021-03-05 苏州康宁杰瑞生物科技有限公司 针对tfpi的单克隆抗体
AU2020385048A1 (en) * 2019-11-13 2022-06-02 Pfizer Inc. Stable aqueous anti-TFPI antibody formulation
CN112552396B (zh) * 2020-12-30 2022-07-12 河南中泽生物工程有限公司 抗非洲猪瘟病毒p54蛋白单克隆抗体、制备方法及应用
JP2021091720A (ja) * 2021-03-03 2021-06-17 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
CN117285632A (zh) * 2022-06-17 2023-12-26 安源医药科技（上海）有限公司 针对tfpi的单克隆抗体及其用途

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US6969586B1 (en) * 1989-05-16 2005-11-29 Scripps Research Institute Method for tapping the immunological repertoire
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
DK261490D0 (da) * 1990-10-31 1990-10-31 Novo Nordisk As New pharmaceutical compound
US5589359A (en) 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
JPH0875736A (ja) * 1994-09-06 1996-03-22 Chemo Sero Therapeut Res Inst ヒト組織因子凝固系インヒビターの定量法
US5902582A (en) 1995-09-05 1999-05-11 Chiron Corporation Use of TFPI inhibitor for treatment of cancer
JP3681206B2 (ja) * 1995-12-26 2005-08-10 株式会社三菱化学ヤトロン 抗ファクターＸａ・ティシュファクターパスウェイインヒビター複合体モノクローナル抗体及びその使用
US20040052799A1 (en) * 1996-11-15 2004-03-18 Astra Aktiebolag Nucleic acid and amino acid sequences relating to Helicobacter pylori for diagnostics and therapeutics
WO1999046289A1 (en) * 1998-03-12 1999-09-16 Human Genome Sciences, Inc. 31 human secreted proteins
WO1999003496A1 (en) * 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Factor ix antihemophilic factor with increased clotting activity
US6617156B1 (en) * 1997-08-15 2003-09-09 Lynn A. Doucette-Stamm Nucleic acid and amino acid sequences relating to Enterococcus faecalis for diagnostics and therapeutics
US6551795B1 (en) * 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
JP2000128803A (ja) * 1998-10-19 2000-05-09 Shionogi & Co Ltd ティッシュ・ファクター・パスウェイ・インヒビター−２抗体
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US20090087878A9 (en) * 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
US20040031072A1 (en) * 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
US20100293669A2 (en) * 1999-05-06 2010-11-18 Jingdong Liu Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
JP4623825B2 (ja) * 1999-12-16 2011-02-02 協和発酵バイオ株式会社 新規ポリヌクレオチド
US20110131679A2 (en) * 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
US7834146B2 (en) * 2000-05-08 2010-11-16 Monsanto Technology Llc Recombinant polypeptides associated with plants
US20040181830A1 (en) * 2001-05-07 2004-09-16 Kovalic David K. Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
DK1282438T3 (da) * 2000-05-10 2005-11-14 Novo Nordisk Healthcare Ag Farmaceutisk sammensætning omfattende en faktor VIIa og en faktor XIII
US7015194B2 (en) * 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
US20020082206A1 (en) * 2000-05-30 2002-06-27 Leach Martin D. Novel polynucleotides from atherogenic cells and polypeptides encoded thereby
AU2001268427B2 (en) * 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
US7214786B2 (en) * 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
GB0101879D0 (en) * 2001-01-24 2001-03-07 Enzyme Res Lab Ltd Anticoagulants and their uses
WO2002094867A2 (fr) * 2001-02-07 2002-11-28 Institut Pasteur Sequence du genome de photorhabdus luminescens souche tto1 et utilisations
US6891085B2 (en) * 2001-04-20 2005-05-10 Pioneer Hi-Bred International, Inc. Nucleic acid encoding the FUS6 antimicrobial polypeptide of Agrotis ipsilon and its use to enhance disease resistance in a plant
CA2387401C (en) * 2001-05-21 2004-10-12 Ecopia Biosciences Inc. Compositions, methods and systems for the production of enediynes
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
BR0213293A (pt) * 2001-10-15 2004-12-21 Chiron Corp Uso de tfpi ou de um análogo de tfpi no tratamento de septicemia
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
US20050108791A1 (en) * 2001-12-04 2005-05-19 Edgerton Michael D. Transgenic plants with improved phenotypes
US20030157082A1 (en) * 2002-01-31 2003-08-21 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer using 140, 1470, 1686, 2089, 2427, 3702, 5891, 6428, 7181, 7660, 25641, 69583, 49863, 8897, 1682, 17667, 9235, 3703, 14171, 10359, 1660, 1450, 18894, 2088, 32427, 2160, 9252, 9389, 1642, 85269, 10297, 1584, 9525, 14124, 4469, 8990, 2100, 9288, 64698, 10480,20893, 33230,1586, 9943, 16334, 68862, 9011, 14031, 6178, 21225, 1420, 32236, 2099, 2150, 26583, 2784, 8941, 9811, 27444, 50566 or 66428 molecules
US7314974B2 (en) * 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
US20060068386A1 (en) * 2002-03-04 2006-03-30 Alexei Slesarev Complete genome and protein sequence of the hyperthermophile methanopyrus kandleri av19 and monophyly of archael methanogens and methods of use thereof
CN100412090C (zh) * 2002-05-01 2008-08-20 舍林股份公司 作为抗凝剂的新的靶向组织因子的血栓调节蛋白融合蛋白
IL149820A0 (en) * 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
WO2004003144A2 (en) * 2002-07-01 2004-01-08 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
DE10239073A1 (de) * 2002-08-26 2004-03-11 Basf Ag Verfahren zur fermentativen Herstellung schwefelhaltiger Feinchemikalien
CA2515583C (en) * 2003-03-07 2015-07-14 Diversa Corporation Hydrolases, nucleic acids encoding them and methods for making and using them
EA015363B1 (ru) * 2003-07-18 2011-06-30 Эмджен Инк. Агенты, специфически связывающие фактор роста гепатоцитов, и их применение
US7871610B2 (en) * 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
ATE463572T1 (de) * 2003-12-03 2010-04-15 Univ Rochester Rekombinanter faktor viii mit erhöhter spezifischer aktivität
WO2005069762A2 (en) * 2004-01-09 2005-08-04 Novozymes Inc. Bacillus licheniformis chromosome
ZA200705695B (en) * 2004-12-21 2009-02-25 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
US20080148432A1 (en) * 2005-12-21 2008-06-19 Mark Scott Abad Transgenic plants with enhanced agronomic traits
EP2361933A3 (en) * 2005-01-26 2012-05-02 Amgen Fremont Inc. Antibodies against interleukin-1 beta
CA2597098C (en) * 2005-02-08 2016-08-02 Steven R. Ledbetter Antibodies to tgfbeta
US8088976B2 (en) * 2005-02-24 2012-01-03 Monsanto Technology Llc Methods for genetic control of plant pest infestation and compositions thereof
WO2006092449A2 (en) * 2005-03-02 2006-09-08 Metanomics Gmbh Process for the production of fine chemicals
WO2007094842A2 (en) * 2005-12-02 2007-08-23 Genentech, Inc. Binding polypeptides and uses thereof
JP2009540018A (ja) * 2006-06-13 2009-11-19 ザイモジェネティクス， インコーポレイテッド Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法
WO2010072691A1 (en) * 2008-12-22 2010-07-01 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
PT2542257T (pt) * 2010-03-01 2017-10-09 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)

Also Published As

Publication number Publication date
ZA201100888B (en) 2012-04-25
CN105944100A (zh) 2016-09-21
WO2010017196A3 (en) 2010-11-04
US20120269817A1 (en) 2012-10-25
KR20180029106A (ko) 2018-03-19
CA2733075A1 (en) 2010-02-11
IL277162B (en) 2021-05-31
CL2016003015A1 (es) 2017-06-30
CR20110066A (es) 2011-05-25
IL210987A (en) 2017-03-30
LT2321356T (lt) 2018-09-10
CA2933259A1 (en) 2010-02-11
KR20160091439A (ko) 2016-08-02
HRP20181095T1 (hr) 2018-09-21
KR101769725B1 (ko) 2017-08-18
BR122017025538A2 (pt) 2021-01-19
NZ731392A (en) 2018-10-26
EP2321356A4 (en) 2013-02-13
AU2016201230A1 (en) 2016-03-17
JP2013500701A (ja) 2013-01-10
IL250640B (en) 2020-10-29
SI2321356T1 (sl) 2018-09-28
SV2011003828A (es) 2011-05-20
US20170342162A1 (en) 2017-11-30
DOP2019000287A (es) 2019-12-15
EP2321356B1 (en) 2018-04-11
JP5801194B2 (ja) 2015-10-28
CN110437335A (zh) 2019-11-12
CA2733075C (en) 2018-10-23
CU20110031A7 (es) 2012-06-21
CA3081514A1 (en) 2010-02-11
AU2018203753A1 (en) 2018-06-21
CU23900B1 (es) 2013-03-28
ECSP11010810A (es) 2011-03-31
IL210987A0 (en) 2011-04-28
NZ714313A (en) 2017-05-26
CL2011000230A1 (es) 2011-06-24
CU20110236A7 (es) 2012-07-31
CN102143979A (zh) 2011-08-03
WO2010017196A2 (en) 2010-02-11
ES2677329T3 (es) 2018-08-01
CN105944100B (zh) 2019-09-17
CA2933259C (en) 2021-07-06
UA112050C2 (uk) 2016-07-25
KR20110043736A (ko) 2011-04-27
KR20190099341A (ko) 2019-08-26
CY1120670T1 (el) 2019-12-11
CA3081514C (en) 2021-12-14
PE20141563A1 (es) 2014-10-24
AU2009279804A1 (en) 2010-02-11
CA3138035A1 (en) 2010-02-11
PL2321356T3 (pl) 2018-10-31
DOP2011000045A (es) 2011-10-31
US20180334509A1 (en) 2018-11-22
SMT201800355T1 (it) 2018-09-13
MX2011001351A (es) 2011-10-12
KR20170005516A (ko) 2017-01-13
AU2009279804B2 (en) 2016-03-24
IL250640A0 (en) 2017-04-30
IL282658A (en) 2021-06-30
TR201807252T4 (tr) 2018-06-21
AU2009279804C1 (en) 2017-01-19
PT2321356T (pt) 2018-07-17
UA120596C2 (uk) 2020-01-10
IL277162A (en) 2020-10-29
BRPI0917418A2 (pt) 2021-01-05
SG10201703066PA (en) 2017-05-30
MY161844A (en) 2017-05-15
EP2321356A2 (en) 2011-05-18
CN110452299A (zh) 2019-11-15
CN102143979B (zh) 2016-08-03
PE20110771A1 (es) 2011-10-14
PH12017502286A1 (en) 2019-11-11
KR101692085B1 (ko) 2017-01-03
CU23880B1 (es) 2013-04-19
DK2321356T3 (en) 2018-07-23
CO6351803A2 (es) 2011-12-20
HUE038648T2 (hu) 2018-11-28

Similar Documents

Publication Publication Date Title
CL2011000230A1 (es) Anticuerpo monoclonal humano aislado que se une al inhibidor de la via del factor tisular (tfpi); composicion farmaceutica que lo comprende; uso para tratar deficiencias adquiridas o geneticas de la coagulacion, o para acortar el tiempo de sangrado.
CL2015001984A1 (es) (divisional de la sol. 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos.
NI201000055A (es) 2&#39; - fluoro - 2&#39; - desoxitetrahidrouridinas como inhibidores de citidina desaminasa.
DOP2012000314A (es) Compuestos, composiciones de tiocetato y metodos de uso
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
CO7160059A2 (es) Formulación líquida
CL2013000304A1 (es) Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
CO6410314A2 (es) Proteínas de unión a il-17
HN2012001223A (es) Antagonistas de pcsk 9
UA109271C2 (uk) Комбінація фітоканабіноїдів та темозоламіду для лікування гліоми
ECSP10010344A (es) Azolilmetiloxiranos, su uso y agentes que los contienen
CL2008002430A1 (es) Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
CU20100032A7 (es) Depsipéptidos cíclicos
CL2011000295A1 (es) Compuestos derivados de pirimidil-amino-benzamida; inhibidores de tirosin-quinasa; y su uso en el tratamiento de la hipertension pulmonar.
CR20110100A (es) Nuevos derivados de sulfamida sustituida
CL2011002548A1 (es) Compuestos derivados de resolviina; composicion farmaceutica; uso de la composicion; kit farmaceutico; combinacion farmaceutica; uso de los compuestos en el tratamiento y/o prevencion de una condicion oftalmica.
MA32776B1 (fr) Inhibiteurs de l&#39;akt et de la p70 s6 kinase
CL2012002887A1 (es) Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer.
CO6361894A2 (es) Composiciones aclaradoras de la piel con inhibidores de acetilcolinesterasa
AR063026A1 (es) Anticuerpos dirigidos contra ccr5 y la utilizacion de los mismos
ECSP088743A (es) Anticuerpos para egfl7 y métodos para su uso
BR112013000779A2 (pt) composições farmacêuticas de combinação, métodos de tratamento de paciente e uso de forma potencializada ativada de anticorpo para receptor at1 de angiotensina ii e forma potencializada ativada de anticorpo para sintase no endotelial
CL2008003602A1 (es) Compuestos derivados de triazolotriazinas y triazolopirazinas sustituidas; composicion farmaceutica; y su uso en el tratamiento y/o profilaxis de trastornos hematologicos.
CL2012003119A1 (es) Composicion farmaceutica para inyeccion que compende una solucion acuosa de ibuprofeno y trometamol, en que la concentracion de ibuprofeno esta entre 2 y 6 mg/ml, la concentracion de trometamol esta entre 1.8 y 5.8 mg/ml, y el ph esta entre 7,0 y 9,5; y su uso para el tratamiento del dolor, la inflamacion o la fiebre.
CL2012000801A1 (es) Composición farmacéutica en solución acuosa que comprende olopatadina y un compuesto derivado de quinolina sustituida, inhibidor de pde4; y uso para el tratamiento de una condición alérgica o inflamatoria del ojo, la nariz o la piel.